Product Description
Mechanisms of Action: BCL2 Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: European Medicines Agency
Approved Indications: None
Known Adverse Events: None
Company: Genta
Company Location: BERKELEY HEIGHTS NJ 07922
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Lymphoid Leukemia|Melanoma|Acute Myeloid Leukemia
Phase 2: Renal Cell Carcinoma|Prostate Cancer|Adenocarcinoma|B-Cell Marginal Zone Lymphoma|Lymphomatoid Granulomatosis|Neuroendocrine Carcinoma|Melanoma|Burkitt Lymphoma|Follicular Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Mantle-Cell Lymphoma|Waldenstrom Macroglobulinemia|Carcinoma, Merkel Cell|T-Cell Cutaneous Lymphoma|Plasmablastic Lymphoma|Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Extranodal NK-T-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Large-Cell Immunoblastic Lymphoma|Adult T-Cell Leukemia-Lymphoma|Intraocular Lymphoma|Leukemia, Plasma Cell|Chronic Lymphoid Leukemia|Colorectal Cancer|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Gastrointestinal Stromal Tumors|Esophageal Cancer|Breast Cancer|Ovarian Cancer|Lung Cancer|Head and Neck Cancer|Kidney Cancer|Bladder Cancer|Male Breast Cancer|Small Cell Lung Cancer|Gastrointestinal Cancer|Squamous Cell Carcinoma|Liver Cancer|Hepatocellular Carcinoma
Phase 1: Oncology Solid Tumor Unspecified|Kidney Diseases|Melanoma|Small Cell Lung Cancer|Large-Cell Immunoblastic Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Mantle-Cell Lymphoma|Diffuse Large B-Cell Lymphoma|Acute Myeloid Leukemia|Chronic Lymphoid Leukemia|Leukemia, Plasma Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|B-Cell Marginal Zone Lymphoma|Adult T-Cell Leukemia-Lymphoma|Follicular Lymphoma|Burkitt Lymphoma|Acute Lymphoid Leukemia|T-Cell Cutaneous Lymphoma|Lymphoma, Non-Hodgkin|Plasmablastic Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| GPK109 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2008-03-01 |
2019-03-18 |
||
| 0462-07-FB | P1 |
Terminated |
Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin |
2012-10-09 |
2024-11-27 |
Primary Endpoints |
|
| NCI-2012-02531 | P1 |
Terminated |
Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia|B-Cell Marginal Zone Lymphoma|Adult T-Cell Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Follicular Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|T-Cell Cutaneous Lymphoma|Plasmablastic Lymphoma|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Large-Cell Immunoblastic Lymphoma |
2009-12-01 |
2019-03-21 |
Treatments |
|
| NCI-2013-00010 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2008-05-01 |
2020-10-26 |
Primary Endpoints|Treatments |
|
| GPK104 | P1 |
Completed |
Kidney Diseases |
2007-11-01 |
2019-03-21 |
Treatments |
|
| NCI-2012-01872 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2005-10-01 |
2024-11-27 |
||
| NCT01200342 | P2 |
Terminated |
Melanoma |
2013-09-01 |
2019-03-19 |
||
| NCI-2012-03134 | P2 |
Terminated |
Gastrointestinal Cancer|Squamous Cell Carcinoma|Esophageal Cancer|Adenocarcinoma |
2010-02-01 |
2020-10-26 |
Primary Endpoints|Treatments |
|
| NCI-2011-00617 | P2 |
Completed |
Adult T-Cell Leukemia-Lymphoma|Lymphomatoid Granulomatosis|Large-Cell Immunoblastic Lymphoma|Follicular Lymphoma|Waldenstrom Macroglobulinemia|Lymphocytic Chronic B-Cell Leukemia|Mantle-Cell Lymphoma|Burkitt Lymphoma|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Intraocular Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin|Plasmablastic Lymphoma|Diffuse Large B-Cell Lymphoma|T-Cell Cutaneous Lymphoma|B-Cell Marginal Zone Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Extranodal NK-T-Cell Lymphoma |
2010-01-01 |
2019-03-21 |
Treatments |
|
| PMH-PHL-011 | P2 |
Completed |
Liver Cancer|Hepatocellular Carcinoma |
2009-01-01 |
2024-11-27 |
||
| GL217 | P2 |
Completed |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
2008-09-01 |
2019-03-21 |
Treatments |
|
| NCI-2012-02885 | P2 |
Terminated |
Male Breast Cancer |
2008-02-01 |
2024-11-27 |
Primary Endpoints |
|
| NCI-2012-03080 | P2 |
Terminated |
Lymphoma, Non-Hodgkin|Follicular Lymphoma |
2007-11-01 |
2020-10-26 |
Primary Endpoints|Treatments |
|
| NCI-2012-03031 | P2 |
Terminated |
Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma |
2007-06-01 |
2024-11-27 |
||
| NCI-2012-01437 | P2 |
Completed |
Waldenstrom Macroglobulinemia |
2007-06-01 |
2020-10-26 |
Primary Endpoints |
|
| NCI-2012-01446 | P2 |
Completed |
Neuroendocrine Carcinoma|Carcinoma, Merkel Cell |
2007-01-01 |
2019-03-21 |
Treatments |
|
| 2004-002094-23 | P2 |
Completed |
Prostate Cancer |
2006-09-29 |
2022-03-12 |
Treatments |
|
| NCI-2012-02600 | P2 |
Completed |
Diffuse Large B-Cell Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma|Lymphoma, Non-Hodgkin |
2006-07-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| NCI-2012-02883 | P2 |
Terminated |
Gastrointestinal Stromal Tumors |
2006-07-01 |
2019-03-21 |
Treatments |
|
| EORTC-30021 | P2 |
Completed |
Adenocarcinoma|Prostate Cancer |
2006-01-01 |
2019-03-21 |
Treatments |
|
| NCI-2012-02790 | P2 |
Completed |
Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia |
2005-11-01 |
2020-10-26 |
Primary Endpoints|Treatments |
|
| AGENDA | P3 |
Completed |
Melanoma |
2011-05-01 |
2019-03-21 |
||
| 2007-003340-30 | P3 |
Completed |
Melanoma |
2011-04-28 |
2022-03-12 |
Treatments |
|
| NCI-2012-02805 | P3 |
Completed |
Acute Myeloid Leukemia |
2007-06-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| GPK103 | P3 |
Terminated |
Melanoma |
2007-05-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/20/2023 |
PubMed |
Bcl-2 expression in cell lines breast cancer and death program. |
|
06/13/2023 |
PubMed |
Metal-Organic Frameworks Facilitate Nucleic Acids for Multimode Synergistic Therapy of Breast Cancer. |
|
02/01/2023 |
PubMed |
[Effect of erastin and G3139 on rat liver mitochondria in chronic alcoholic intoxication]. |